界面新闻记者 |黄华界面新闻编辑 |许悦2月21日,据国家药监局药品审评中心(CDE)公示,默沙东(MSD)申报的1类新药注射用MK-6070已获得临床试验默示许可,拟开发治疗小细胞肺癌。这意味着,这款在研新药将在中国进入临床研究阶段。MK-6070是默沙东收购而来的管线,而在收购约7个月后,默沙东和第一三共(Daiichi Sankyo)宣布在全球范围内联合开发和商业化该管线,默沙东独家保留在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.